Liver graft dysfunction due to hepatitis C infection
https://doi.org/10.23873/2074-0506-2010-0-3-4-37-45
Abstract
We analyzed natural history of recurrent HCV-infection after cadaveric liver transplantation (LTx) in 38 cases. The mean follow-up time was 23.8 (95% CI, 18.4; 29.2) mo after LTx. There were latent course in 19 pts, and active hepatitis in another 19 pts in the 1st post-LTx year. Active hepatitis has been associated with CMV-infection, acute cellular rejection and methylprednisolon pulse-therapy. Liver biopsy had shown advanced fibrosis or cirrhosis in 19% cases independently on latent or active course. In 5 out 8 pts with latent course of HCV-infection in the 1st y., the active hepatitis developed up to the end of the 2nd y. FU. Two cases of fibrosing cholestatic hepatitis resulted in the death or retransplantation. Two cases of unusual course of recurrent HCV-infection described (i.e. fulminant liver failure without cholestasis).
About the Authors
V. E. Syutkin
N.V. Sklifosovsky Research Institute of Emergency Care; Moscow State University of Medicine and Dentistry
Russian Federation
Department of Transplantology and Artificial Organs
Russian Federation
Department of Transplantology and Artificial Organs
O. I. Andreitseva
N.V. Sklifosovsky Research Institute of Emergency Care; Moscow State University of Medicine and Dentistry
Russian Federation
Department of Transplantology and Artificial Organs
Russian Federation
Department of Transplantology and Artificial Organs
A. V. Chzhao
N.V. Sklifosovsky Research Institute of Emergency Care; Moscow State University of Medicine and Dentistry
Russian Federation
Department of Transplantology and Artificial Organs
Russian Federation
Department of Transplantology and Artificial Organs
References
1. Terrault N.A., Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12: 1192–204.
2. Gish R.G., Afdhal N.H., Dieterich D.T., Reddy K.R. Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol 2005; 3: 311–8.
3. Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17–35.
4. Berenguer M., Prieto M., Rayon J.M. et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32:852–8.
5. Berenguer M., Palau A., Fernandez A. et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067–76.
6. Thuluvath P.J., Krok K.L., Segev D.L. et al. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States. Liver Transpl 2007;13: 719–24.
7. Tsoulfas G., Goulis I., Giakoustidis D. et al. Hepatitis C and liver transplantation. HIPPOKRATIA 2009, 13, 4: 211–5.
8. Demetris A.J. Evolution of Hepatitis C Virus in Liver Allografts. Liver Transpl 2009; 15: 35–41.
9. Gane E.J. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008;14 (suppl 2):36–44.
10. Ramirez S., Perez-Del-Pulgar S., Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl 2008;14 (suppl 2): 27–35.
11. McCaughan G.W., Shackel N.A., Bertolino P., Bowen D.G. Molecular and cellular aspects of hepatitis C virus reinfection after liver transplantation: how the early phase impacts on outcomes. Transplantation 2009; 87: 1105–11.
12. Haque M., Hashim A., Greanya E.D. et al. Spontaneous clearance of hepatitis C infection post-liver transplant: A rare but real phenomenon? A case report and review of the literature. Ann Hepatol. 2010; 9: 202–6.
13. Pelletier S.J., Iezzoni J.C., Crabtree T.D. et al. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus. Liver Transpl 2000; 6: 44–53.
14. Testa G., Crippin J.S., Netto G.J. et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000; 6: 553–61.
15. Rosen H.R., Gretch D.R., Oehlke M. et al. Timing and severity of initial HCV recurrence as predictors of long-term liver allograft injury. Transplantation 1998; 65: 1178–82.
16. Neumann U.P., Berg T., Bahra M. et al. Fibrosis progression after liver transplantation patients with recurrent hepatitis C. J Hepatol 2004; 41: 830–6.
17. Baiocchi L., Angelico M., Petrolati A. et al. Correlation between liver fibrosis and inflammation in patients transplanted for HCV-liver disease. Am J Transplant 2008; 8: 673–8.
18. Rosen H.R., Chou S., Corless C.L. et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997; 64:721–6.
19. Razonable R.R., Burak K.W., van Cruijsen H. et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002; 35: 974–81.
20. Humar A., Kumar D., Raboud J. et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002; 2: 461–6.
21. Burak K.W., Kremers W.K., Batts K.P. et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362–9.
22. Nebbia G., Mattes F.M., Cholongitas E. et al. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transpl. 2007; 13: 130–5.
23. Humar A., Washburn K., Freeman R. et al. An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. Liver Transpl 2007; 13:1422–7.
24. Charlton M., Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5(suppl): 107–14.
25. Sreekumar R., Gonzalez-Koch A., Maor-Kendler Y. et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32: 1125–30.
26. Prieto M., Berenguer M., Rayon J.M. et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999; 29: 250–6.
27. Zimmermann T., Otto C., HoppeLotichius M. et al. Risk factors in patients with rapid recurrent hepatitis C virus-related cirrhosis within 1 year after liver transplantation Transplant Proc. 2009;41:2549–56.
28. Bahra M., Neumann U.P., Jacob D. et al. Repeated steroid pulse therapies in HCVpositive liver recipients: significant risk factor for HCV-related graft loss. Transplant Proc. 2005; 37: 1700–2.
29. Narang T.K., Ahrens W., Russo M.W. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl. 2010;16:1228 –35.
30. Wiesner R.H., Sorrell M., Villamil F. International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9 (suppl 3): 51–9.
Review
For citations:
Syutkin V.E., Andreitseva O.I., Chzhao A.V. Liver graft dysfunction due to hepatitis C infection. Transplantologiya. The Russian Journal of Transplantation. 2010;(3-4):37-45. (In Russ.) https://doi.org/10.23873/2074-0506-2010-0-3-4-37-45
Views:
605
